Vetenskapliga publikationer - Alligator Bioscience

ATOR-1017, a 4-1BB Antibody Developed for Tumor-Directed Immunotherapy of Cancer

D Werchau, A Rosén, M Eriksson, S Järnum, C Furebring and K Enell Smith, Poster SITC November 9, 2019

Potent Tumor-Directed T cell Activation and Tumor Inhibition Induced by a 4-1BB x 5T4 ADAPTIR™ Bispecific Antibody

M Nelson, R Miller, R Bader, D Werchau, A Nilsson, L Ljung, A Deronic, A Chunyk, L Schultz, C McMahan, D Bienvenue, A Dahlman, S Fritzell, M Askmyr, G Hernandez-Hoyos, Poster SITC November 9, 2019

4224, a tumor exosome-transforming antibody targeting CD40 and EpCAM, induces superior anti-tumor effects compared to monospecific CD40 antibody

Adnan Deronic, Laura von Schantz, Mia Thagesson, Kristine Smedenfors, Christina Sakellariou, Lill Ljung, Fredrika Carlsson, Doreen Werchau, Malin Lindstedt, Peter Ellmark, Karin Hägerbrand, CICON, 26 september 2019

A first-in-human, multicenter, open-label, phase 1 study in patients with advanced and/or refractory solid malignancies to evaluate the safety of intravenously administered ATOR-1015

Jeffrey Yachnin, Gustav J Ullenhag, Ana Carneiro, Dorte Nielsen, Kristoffer Staal Rohrberg, Anne Månsson Kvarnhammar, Anna Dahlman, Erika Bågeman, Camilla Wennersten , Charlotte Astrid Russell., Poster ASCO 1 juni 2019,

RUBY TM – A novel recombinant universal bispecific antibody format for generation of bsAb with outstanding stability, manufacturability and shorter development timelines

A Säll, M Levin, B Nyesiga, M Mårtensson, S Fritzell, K Hägerbrand, C Furebring, L von Schantz, Poster PEGS 11 April 2019

ATOR-1144 is a tumor-directed CTLA-4 x GITR bispecific antibody that acts by depleting Tregs and activating effector T cells and NK cells

S Fritzell, M Levin, A Dahlman, I Åberg, M Johansson, M Winnerstam, K Enell Smith, P Ellmark, C Furebring, P Norlén, A Månsson Kvarnhammar, AACR Annual Meeting April 2, 2019

Preclinical safety and efficacy of a tumor-directed T cell activating 4-1BB x 5T4 ADAPTIR™ bispecific antibody

A Dahlman, M Nelson, J Bannink, Starrla Johnson, D Werchau, A Nilsson, L Ljung, G Blahnik-Fagan, R Bader, P Ellmark, M Askmyr, G Hernandez-Hoyos, C McMahan, S Fritzell, AACR 1 april 2019,

The CTLA-4 x OX40 bispecific antibody ATOR-1015 induces anti-tumor effects through tumor-directed immune activation

Anne Månsson Kvarnhammar, Niina Veitonmäki, Karin Hägerbrand, Mia Thagesson, Doreen Werchau, Kristine Smedenfors, Anna Dahlman, Anna Rosén, Maria Johansson, Ida Åberg, Per Norlén, Christina Furebring and Peter Ellmark, SITC 9 november 2018

ATOR-1017, a tumor directed Fcγ-receptor cross-linking dependent 4-1BB agonistic antibody

Karin Enell Smith, Anna Rosén, Anna Dahlman, Karin Barchan, Ida Åberg, Doreen Werchau, Mia Thagesson, Niina Veitonmäki, Christina Furebring, Peter Ellmark, SITC 9 november 2018

Potent Tumor-Directed T cell Activation and Tumor Inhibition Induced by a 4-1BB x 5T4 ADAPTIR™ Bispecific Antibody

Michelle Nelson, Gabriele Blahnik-Fagan, Robert Bader, Doreen Werchau, Anneli Nilsson, Lill Ljung, Jeannette Bannink, Danielle Mitchell, Lynda Misher, Catherine McMahan, David Bienvenue, Maria Askmyr, Anna Dahlman, Peter Ellmark, Gabriela Hernandez-Hoyos, Sara Fritzell, SITC 9 november 2018

ATOR-1017; a 4-1BB antibody designed for superior safety/efficacy profile in cancer immunotherapy

Eva Dahlén, Anna Rosén, Adnan Deronic, Karin Barchan, Anna Dahlman, Peter Ellmark, Tina Furebring och Karin Enell Smith., 4th CRI-CIMT-EATI-AACR International Cancer lmmunotherapy Conference 30 september 2018.

The agonistic CD40 antibody improves T cell responses and delays growth of a syngeneic tumor in an ovalbumin vaccination model

Adnan Deronic, Anneli Nilsson, Mia Thagesson, Doreen Werchau, Niina Veitonmäki, Per Norlén, Christina Furebring and Peter Ellmark, World Preclinical Congress June 2018

CTLA-4 x OX40 bispecific antibody ATOR-1015 induces anti-tumor effects through tumor-directed immune activation

Anne Månsson Kvarnhammar, Niina Veitonmäki, Karin Hägerbrand, Mia Thagesson, Doreen Werchau, Kristine Smedenfors, Anna Rosén, Maria Johansson, Per Norlén, Christina Furebring and Peter Ellmark, Poster CIMT 16 May 2018

Tumor Antigen-dependent T Cell Activation And Tumor Localization Induced By A Novel 4-1BB X 5T4 ADAPTIR™ Bispecific Antibody

Sara Fritzell, Doreen Werchau, Maria Askmyr, Niina Veitonmäki, Anneli Nilsson, Adnan Deronic, Mia Thagesson, Anna Säll, Laura von Schantz, Robert Bader, Gabriele Blahnik-Fagan, Michelle Nelson, David Bienvenue, Gabriela Hernandez-Hoyos, Peter Ellmark , Poster CIMT 16 May 2018

Activation of the CD137 Pathway in T cells by a CD137 x 5T4 bispecific ADAPTIR™ Molecule Requires Co-engagement of CD137 and 5T4

Gabriele Blahnik-Fagan, Robert Bader, Jeannette Bannink, Danielle Mitchell, Lynda Misher, Cathy McMahan, David Bienvenue, Laura von Schantz, Eva Lindqvist, Doreen Werchau, Anneli Nilsson, Maria Askmyr, Niina Veitonmäki, Sara Fritzell, Peter Ellmark, Michelle Nelson, and Gabriela Hernandez-Hoyos, Poster AAI 5 May 2018

Design and Generation of Bispecific Antibodies for Immuno-Oncology

von Schantz L, Säll A, Carlsson F, Thorulffsson M, Petersson J, Tsiobanelis K, Nyesiga B, Jansson K, Rosén A, Hägerbrand K, Dahlman A, Månsson-Kvarnhammar A, Veitonmäki N and Furebring C., Poster PEGS 2 May 2018

Screening, Optimization and Characterization of a Novel 4-1BB x 5T4 ADAPTIR™ Bispecific Antibody

von Schantz L, Misher L, Mitchell D, Gruswitz F, Woodruff B, Daugherty M, Aguilar M, Huntington K, Bader R, Blahnik-Fagan G, Säll A, Werchau D, Thagesson M, Nilsson A, Deronic A, Askmyr M, Veitonmäki N, Fritzell S, Ellmark P, Hernandez-Hoyos G and Bienvenue D., Poster PEGS 2 May 2018

CTLA-4 x OX40 bispecific antibody ATOR-1015 induces anti-tumor effects through tumor-directed immune activation

Veitonmäki N, Månsson Kvarnhammar A, Fritzell S, Enell Smith K, Thagesson M, Werchau D, Hägerbrand K, Rosén A, Johansson M, Norlén P, Furebring C, Ellmark P, Poster AACR 17 April 2018

Bispecific antibodies in cancer immunotherapy

Eva Dahlén, Niina Veitonmäki and Per Norlén, Therapeutic advances in vaccines and immunotherapy, 2018, Vol. 6(1) 3–17,